These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25396679)

  • 1. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.
    Bueno R; Hughes E; Wagner S; Gutin AS; Lanchbury JS; Zheng Y; Archer MA; Gustafson C; Jones JT; Rushton K; Saam J; Kim E; Barberis M; Wistuba I; Wenstrup RJ; Wallace WA; Hartman AR; Harrison DJ
    J Thorac Oncol; 2015 Jan; 10(1):67-73. PubMed ID: 25396679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
    Eguchi T; Kadota K; Chaft J; Evans B; Kidd J; Tan KS; Dycoco J; Kolquist K; Davis T; Hamilton SA; Yager K; Jones JT; Travis WD; Jones DR; Hartman AR; Adusumilli PS
    Oncotarget; 2016 Jun; 7(23):35241-56. PubMed ID: 27153551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
    Rakha E; Pajares MJ; Ilie M; Pio R; Echeveste J; Hughes E; Soomro I; Long E; Idoate MA; Wagner S; Lanchbury JS; Baldwin DR; Hofman P; Montuenga LM
    Eur J Cancer; 2015 Sep; 51(14):1897-903. PubMed ID: 26235745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.
    Wistuba II; Behrens C; Lombardi F; Wagner S; Fujimoto J; Raso MG; Spaggiari L; Galetta D; Riley R; Hughes E; Reid J; Sangale Z; Swisher SG; Kalhor N; Moran CA; Gutin A; Lanchbury JS; Barberis M; Kim ES
    Clin Cancer Res; 2013 Nov; 19(22):6261-71. PubMed ID: 24048333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
    Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
    Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
    Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
    Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.
    Chen L; Kurtyka CA; Welsh EA; Rivera JI; Engel BE; Muñoz-Antonia T; Yoder SJ; Eschrich SA; Creelan BC; Chiappori AA; Gray JE; Ramirez JL; Rosell R; Schabath MB; Haura EB; Chen DT; Cress WD
    Oncotarget; 2016 Dec; 7(50):82254-82265. PubMed ID: 27756884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.
    Warf MB; Fosso PG; Hughes E; Perry M; Brown KL; Reid JE; Kolquist KA; Wagner S; Gutin A; Roa B
    Biomark Med; 2015; 9(9):901-10. PubMed ID: 26158298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.
    Seike M; Yanaihara N; Bowman ED; Zanetti KA; Budhu A; Kumamoto K; Mechanic LE; Matsumoto S; Yokota J; Shibata T; Sugimura H; Gemma A; Kudoh S; Wang XW; Harris CC
    J Natl Cancer Inst; 2007 Aug; 99(16):1257-69. PubMed ID: 17686824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings.
    Ogawa H; Uchino K; Tanaka Y; Shimizu N; Okuda Y; Tane K; Tauchi S; Nishio W; Maniwa Y; Yoshimura M
    Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):34-9. PubMed ID: 25911680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy.
    Leeman JE; Rimner A; Montecalvo J; Hsu M; Zhang Z; von Reibnitz D; Panchoo K; Yorke E; Adusumilli PS; Travis W; Wu AJ
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):138-145. PubMed ID: 27839909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
    Yamauchi Y; Safi S; Muley T; Warth A; Herth FJF; Dienemann H; Hoffmann H; Eichhorn ME
    Lung Cancer; 2017 Dec; 114():62-67. PubMed ID: 29173768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Node-negative non-small cell lung cancer: pathological staging and survival in 1765 consecutive cases.
    Robinson BM; Kennedy C; McLean J; McCaughan BC
    J Thorac Oncol; 2011 Oct; 6(10):1691-6. PubMed ID: 21869717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid component and tumor size correlate with prognosis of stage IB lung adenocarcinoma.
    Xu S; Xi J; Jiang W; Lu S; Wang Q
    Ann Thorac Surg; 2015 Mar; 99(3):961-7. PubMed ID: 25633461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
    Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma.
    Raz DJ; Ray MR; Kim JY; He B; Taron M; Skrzypski M; Segal M; Gandara DR; Rosell R; Jablons DM
    Clin Cancer Res; 2008 Sep; 14(17):5565-70. PubMed ID: 18765549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated MACC1 expression predicts poor prognosis in small invasive lung adenocarcinoma.
    Guo T; Zhao S; Li Z; Li F; Li J; Gu C
    Cancer Biomark; 2018; 22(2):301-310. PubMed ID: 29630522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
    Hung JJ; Wu YC; Chou TY; Jeng WJ; Yeh YC; Hsu WH
    Ann Thorac Surg; 2016 Apr; 101(4):1346-53. PubMed ID: 26794883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cigarette smoking on survival and tumor invasiveness in clinical stage IA lung adenocarcinoma.
    Maeda R; Yoshida J; Ishii G; Hishida T; Nishimura M; Nagai K
    Ann Thorac Surg; 2012 May; 93(5):1626-32. PubMed ID: 22421592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.